FindTrial
Sign In

Bone metastasis response to immune checkpoint inhibitors in cancer patients: a systematic review

Bone metastasis response to immune checkpoint inhibitors in cancer patients: a systematic review - Bone metastasis response to immune checkpoint inhibitors in cancer patients: a systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000053707
Enrollment
Unknown
Registered
2024-02-26
Start date
2024-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone metastases of various cancers

Interventions

None listed

Sponsors

Department of Orthopaedic Surgery Nara Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Studies reporting response rates specific for bone metastases in patients treated with ICIs were included;

Exclusion criteria

Exclusion criteria: reports of fewer than 5 cases were excluded. Only English- and Japanese-language literature was included, with no restriction on the year of publication. Only human subjects were included; animals were excluded.

Design outcomes

Primary

MeasureTime frame
response rate of ICI for bone metastases (RECIST[13], MDA criteria [14][Table 2]).—

Countries

Japan,Europe

Contacts

Public ContactShinji Tsukamoto

Nara Medical University Department of Orthopaedic Surgery

shinji104@mail.goo.ne.jp+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026